Business Context and Reporting Period
This Form 8-K was filed by Zafgen, Inc. on March 8, 2016, reporting events that occurred on March 3, 2016. The filing addresses corporate governance changes, specifically the election of a new director to the Board of Directors. Note: The request metadata references "Larimar Therapeutics, Inc.," but the source text explicitly identifies the registrant as Zafgen, Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report focused solely on personnel and governance matters.
Material Changes
- Board Election: Thomas O. Daniel, M.D., was elected as a Class I director on March 3, 2016.
- Term: Dr. Daniel will serve until the 2018 annual meeting of stockholders or until a successor is elected.
- Compensation: As a non-employee director, Dr. Daniel will receive cash and equity compensation pursuant to the Company's standard program, subject to Board approval.
Outlook, Risks, and Management Commentary
Management Commentary: The filing highlights Dr. Daniel's extensive background in biopharmaceutical research and leadership, including his current role as Chairman of Celgene Research and previous roles at AmbRx Inc., Amgen Inc., and Immunex. He brings experience in cellular therapy, protein-based biotherapeutics, and academic research.
Risks and Contingencies: The filing explicitly states there are no arrangements or understandings between Dr. Daniel and any other person regarding his election, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the exact compensation package (cash and equity) approved by the Board for Dr. Daniel.
- Confirm the impact of this appointment on the composition of Board committees (e.g., Audit, Compensation, Nominating).
- Review the press release (Exhibit 99.1) for additional strategic context regarding the appointment.
- Clarify the discrepancy between the request metadata (Larimar Therapeutics) and the filing registrant (Zafgen, Inc.).